| Summary: | Background : pathogenic fungi infection is still an
issue in medical discourse nowadays. In the last two
decades, Candida sp. has been reported to change from
being the opportunist fungus that rarely caused
nosocomial infection to be the opportunist fungus that
most often cause nosocomial infection. Candidiasis
treatment that is effective and efficient is needed,
but to this day there are many antifungal treatments
that is improper and irrational in dosage, thus
resulting in resistance. One of the fungi that is
resistant to conventional antifungal treatment is
Candida sp resistant Itrakonazol and Ketokonazol. The
effort in finding new antifungal can be done through
pharmacomodulation of compounds which activity has been
known. Mustofa et al (2002) have succeeded in
developing derivative compound 1,10-Fenantrolin, that
is in the form of Fenatrolin 2 compound in the way of
modifying the structure of the compound.
Objective : to find out the antifungal potential, which
is the Minimum Inhibitory Concentration (MIC) of the
Fenantrolin 2 compound against strain of Candida sp
resistant Itrakonazol and Ketokonazol.
Methods : this research was conducted with experimental
descriptive design and antifungal potential through
microboth dilution method.
Results : the result obtained is based on the test
showing that a strain of Candida sp resistant
Itrakonazol and Ketokonazol growth can be restricted by
Fenantrolin 2 compound in 3,175 µg/ml concentrations.
Conclusion : Fenantrolin 2 has the antifungal potential
towards Candida sp resistant Itrakonazol and
Ketokonazol which action mechanism is not fully
understood.
|
|---|